The Recombinant DNA Advisory Committee (RAC) no longer exists under that name, and it no longer reviews individual research protocols. From 1974 to 2019, RAC was NIH’s public advisory body on the safety and societal implications of recombinant DNA research, including case-by-case review of higher-risk experiments and, for a period, individual human gene transfer (gene therapy) protocols. In April 2019, NIH restructured RAC into the Novel and Exceptional Technology and Research Advisory Committee (NExTRAC), narrowed its scope to forward-looking policy advice rather than protocol-specific review, and shifted day-to-day oversight of individual protocols onto the Institutional Biosafety Committee (IBC), the Institutional Review Board (IRB), and, for gene therapy products specifically, the FDA. This guide covers RAC’s historical role, why NIH restructured it, what NExTRAC does today, and where research administrators should actually look for oversight of the work RAC used to review.
What RAC Was (1974-2019)
NIH established the Recombinant DNA Advisory Committee in 1974, in the period of scientific concern that produced the February 1975 Asilomar Conference on Recombinant DNA and, in 1976, the first version of the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules. RAC was chartered as a federal advisory committee under the Federal Advisory Committee Act (FACA), which meant its meetings were public and its deliberations were a matter of public record — a deliberately open model for overseeing an emerging and, at the time, publicly contentious technology.
RAC’s core functions over its roughly 45-year run were to advise the NIH Director on the safety and policy implications of recombinant and synthetic nucleic acid research, and to provide case-by-case review of the highest-risk categories of experiments under the NIH Guidelines (what the Guidelines still label Section III-A, major actions requiring Director-level review). RAC also became closely associated with a specific, higher-profile role: reviewing individual human gene transfer (gene therapy) research protocols before they could proceed, a function it took on as that field emerged in the early 1990s.
The Human Gene Transfer Era and Why RAC’s Role Became Contested
NIH approved the first human gene transfer protocol in 1990, and the field grew quickly through the 1990s. Individual gene therapy protocols went through RAC’s public review process in addition to standard IBC and IRB review — a level of national-level, protocol-specific scrutiny not applied to most other categories of research. The 1999 death of a participant in a University of Pennsylvania gene therapy trial (a case widely documented in the bioethics and research-oversight literature) sharpened public and regulatory attention on gene transfer research generally and contributed to a period of intensified federal scrutiny of the field, including at FDA.
Over the following two decades, FDA’s own authority over human gene transfer products — exercised through the Investigational New Drug (IND) process, the same pathway that governs any investigational biologic or drug — became the substantive regulatory backbone for gene therapy trials, in parallel with RAC’s advisory review. By the 2010s, NIH itself concluded that requiring individual protocols to go through both FDA’s IND review and RAC’s separate public review created duplicative reporting burden for sponsors and institutions without a correspondingly distinct safety benefit, since FDA’s authority over the product and IRB/IBC authority over the local conduct of the trial already covered the ground RAC’s protocol-specific review was covering.
The 2019 Restructuring: RAC Becomes NExTRAC
NIH’s Office of Science Policy (OSP), which administers the NIH Guidelines, proposed streamlining this oversight in an August 2018 Federal Register notice and finalized the change through a final action published in April 2019. Effective with that action, NIH eliminated the requirement that individual human gene transfer protocols be submitted to RAC/OSP for separate national-level review and reporting, and renamed the committee the Novel and Exceptional Technology and Research Advisory Committee (NExTRAC) — a name chosen to reflect a broader, more forward-looking charge: advising NIH on emerging biotechnologies generally, rather than sitting as a standing review body for individual protocols.
This was a change in function, not a quiet discontinuation. NIH’s own public statements framed it as streamlining redundant gene-therapy oversight while creating a body better suited to advise on technologies the original RAC charter never anticipated — genome editing, synthetic biology, gene drives, and other novel biotechnologies raising public-health or biosecurity questions similar in kind to the ones that justified RAC’s creation in 1974, just applied to a much wider and faster-moving set of techniques.
What NExTRAC Does Today
NExTRAC continues RAC’s role as a chartered FACA public advisory committee reporting to the NIH Director, with open meetings and published materials. Its current charge is deliberately broader and less protocol-specific than RAC’s later years: NExTRAC advises NIH leadership and OSP on the science, safety, and societal/ethical questions raised by novel and exceptional biotechnologies as a category, rather than reviewing individual research protocols as a matter of routine. That means an institution running a human gene transfer or other emerging-biotechnology protocol today does not submit that protocol to NExTRAC for case-by-case approval the way it once would have to RAC.
A narrow exception carries over from the old Section III-A structure: NIH Guidelines section III-A “major actions” — the small category of experiments of particular public-health or biosecurity concern that require NIH Director-level review before initiation — can still route through NExTRAC (or a similarly constituted body) for advisory input to the Director, since that category was never specific to human gene transfer. In practice this affects a very small fraction of covered research; the routine, protocol-specific national review that defined RAC’s gene-therapy-era public profile is what was actually eliminated.
Where Protocol-Level Oversight Actually Sits Now
For the great majority of research that would once have touched RAC, oversight is now distributed across the bodies that were already doing parallel review, rather than concentrated in one national committee:
- Institutional Biosafety Committee (IBC) — reviews and approves the recombinant/synthetic nucleic acid research itself under the NIH Guidelines, assigns containment requirements, and remains the mandatory local review body for essentially all covered r/sNA research, including most human gene transfer work. See CASRAI’s Institutional Biosafety Committee (IBC) entry.
- Institutional Review Board (IRB) — reviews human gene transfer and other protocols involving human participants for participant risk, informed consent, and research-ethics compliance, running in parallel with IBC review rather than as a substitute for it. See CASRAI’s IRB entry.
- FDA — regulates human gene transfer products directly through the IND process (and, for licensed products, the biologics licensing pathway), the same substantive safety-and-efficacy authority FDA exercises over any investigational drug or biologic.
- NIH OSP — continues to administer the NIH Guidelines themselves, maintain the IBC registration system, and issue Guidelines updates and notices, independent of NExTRAC’s advisory function.
The net effect is that oversight of an individual protocol did not weaken when RAC’s role narrowed — it consolidated onto the review bodies (IBC, IRB, FDA) that already had substantive, product- and participant-level authority, while the advisory function RAC also performed continued under NExTRAC with a broader remit.
Practical Implications for Research Administrators
- If an older institutional SOP, biosafety policy, or human-gene-transfer protocol template still references “RAC review” or “RAC submission” as a required step, that language is stale as of April 2019 and should be updated to reflect current IBC/IRB/FDA requirements rather than a defunct national review step.
- Do not assume a human gene transfer protocol needs case-by-case NExTRAC approval before initiation — confirm current requirements directly against the NIH Guidelines and OSP notices, since the III-A “major actions” exception still applies to a narrow category of research.
- NExTRAC meeting materials and working-group reports remain useful reading for institutions tracking where NIH policy on emerging biotechnology (gene editing, synthetic biology, gene drives, and similar) is likely headed, even though they no longer function as protocol-approval records the way older RAC minutes sometimes did.
- Confirm your institution’s IBC composition and registration are current under the NIH Guidelines — see CASRAI’s guide on what the NIH Guidelines require for the full compliance checklist.
Frequently Asked Questions
When did the Recombinant DNA Advisory Committee stop existing?
NIH restructured and renamed RAC as the Novel and Exceptional Technology and Research Advisory Committee (NExTRAC) through a final action published in the Federal Register in April 2019, following a proposal published for public comment in August 2018. RAC had operated under that name since 1974.
Does NExTRAC review individual gene therapy or gene transfer protocols?
No, not as a matter of routine. The 2019 restructuring specifically eliminated the requirement that individual human gene transfer protocols be submitted for separate national-level RAC/OSP review. NExTRAC’s current role is advising NIH leadership on emerging biotechnology policy generally; protocol-level review for human gene transfer research now runs through the IBC, IRB, and FDA. A narrow exception remains for NIH Guidelines Section III-A “major actions,” which can still receive Director-level advisory input.
Is IBC or IRB review still required for human gene transfer research if RAC no longer reviews it?
Yes. IBC review under the NIH Guidelines and IRB review under human-subjects regulations were always required in parallel with RAC review, not replaced by it. Removing the RAC/NExTRAC layer did not remove IBC or IRB review — both remain mandatory for covered human gene transfer research.
Why did NIH restructure RAC instead of simply retiring it?
NIH’s stated rationale was that RAC’s routine gene-therapy protocol review had become substantively duplicative of FDA’s IND-based authority over the same products, while the committee’s original broader purpose — public advisory input on the safety and societal implications of a novel biotechnology — remained valuable and, if anything, applicable to a wider range of emerging technologies than recombinant DNA research alone by 2019. NExTRAC preserves that advisory function under a broader charge rather than discontinuing it.
What does “NExTRAC” stand for?
Novel and Exceptional Technology and Research Advisory Committee. It is chartered, like RAC before it, as a public advisory committee under the Federal Advisory Committee Act, reporting to the NIH Director through NIH’s Office of Science Policy.
This page summarizes RAC’s historical role and NExTRAC’s current function for research-administration purposes. Institutions should consult NIH’s Office of Science Policy directly for the current NIH Guidelines text, NExTRAC charter, and meeting materials before making protocol-specific compliance determinations.
